Bristol Phase 3: Optivo + Yervoy significant efficacy benefit v. chemo as 1st line in metastatic colorectal cancer

 Opdivo (nivolumab) plus Yervoy (ipilimumab) demonstrates statistically significant and clinically meaningful improvement in progression-free survival compared to investigator’s choice of chemotherapy

Combination of Opdivo plus Yervoy is the only dual immunotherapy regimen to demonstrate significant efficacy benefit compared to chemotherapy as first line treatment in MSI-H/dMMR metastatic colorectal cancer

https://www.biospace.com/article/releases/bristol-myers-squibb-announces-phase-3-checkmate-8hw-trial-evaluating-opdivo-nivolumab-plus-yervoy-ipilimumab-/